PMID: 8967704Dec 15, 1996Paper

Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease

Annals of Internal Medicine
A A KroonA F Stalenhoef

Abstract

Apheresis of low-density lipoprotein (LDL) is an effective lipid-lowering treatment in hypercholesterolemic patients who have coronary artery disease and are refractory to drugs. More aggressive lipid-lowering therapy may further slow the progression of atherosclerosis. To compare the effect of LDL apheresis and simvastatin therapy with the effect of simvastatin therapy alone on the progression of peripheral vascular disease. Open, randomized, single-center study. University hospital. 42 men with primary hypercholesterolemia (total cholesterol level > 8.0 mmol/L) and extensive coronary atherosclerosis. Biweekly apheresis of LDL plus simvastatin, 40 mg/d (n = 21), or simvastatin, 40 mg/d (n = 21), for 2 years. Lipid and lipoprotein levels, changes in hemodynamically significant stenoses in the aortotibial tract (measured by ankle:arm systolic blood pressure ratio combined with Doppler spectrum analysis of the femoral artery), and changes in the mean intima-media thickness of three carotid artery segments. Mean baseline LDL cholesterol levels decreased from 7.8 to 3.0 mmol/L in the apheresis and simvastatin group and from 7.9 to 4.1 mmol/L in the simvastatin-only group; mean lipoprotein(a) levels decreased from 57.0 to 44.5 mg/dL...Continue Reading

Citations

Jul 25, 2009·Current Treatment Options in Cardiovascular Medicine·Puja K MehtaLaurence S Sperling
Mar 6, 2003·Atherosclerosis·Gilbert R Thompson
Mar 22, 2001·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·S KojimaM Kuramochi
May 24, 2001·The New England Journal of Medicine·W R Hiatt
Nov 11, 1999·Current Opinion in Lipidology·K Kajinami, H Mabuchi
Jan 27, 2012·Seminars in Dialysis·Jeffrey L Winters
Aug 1, 1997·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·B R Gordon, S D Saal
May 5, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·T Yamamoto, T Yamashita
Dec 14, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Wai Ping LeeJulian Halcox
Aug 15, 2001·Lancet·A S WierzbickiD P Mikhalidis
Dec 9, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·K G ParhoferP Schwandt
Feb 20, 2016·Endocrinology and Metabolism Clinics of North America·Patrick M Moriarty, Linda Hemphill
Mar 30, 2005·Expert Opinion on Drug Safety·Rodrigo AlonsoPedro Mata
Jan 30, 2013·Atherosclerosis. Supplements·Alfonso RamunniPaola Brescia
Jan 30, 2013·Atherosclerosis. Supplements·Claas L NeumannVolker Schettler
Aug 2, 2011·Cardiology Clinics·Deepthi VodnalaRobert D Brook
Jul 28, 2009·Medicina clínica·Luis Javier Alvarez-FernándezMaría Vicente Santiago
Mar 29, 2008·Atherosclerosis·G R Thompson, UNKNOWN HEART-UK LDL Apheresis Working Group
Aug 13, 2011·Journal of Clinical Apheresis·Jeffrey L Winters
Sep 2, 2010·Journal of Clinical Apheresis·Rasheed A BalogunAndre A Kaplan
Jul 15, 2006·Annals of Vascular Surgery·Mohamad E AlnaebGeorge Hamilton
Mar 21, 2006·Atherosclerosis·Jeff Thompsen, Paul D Thompson
Jul 31, 1998·The American Journal of Medicine·C M Ballantyne
May 26, 2015·Current Atherosclerosis Reports·Vijay G Bhoj, Bruce S Sachais
May 6, 2015·Cardiology Clinics·Patrick M Moriarty, Linda Hemphill
Jun 21, 2016·Journal of Clinical Apheresis
Mar 18, 2016·Vascular and Endovascular Surgery·Lorena GonzalezVivian Gahtan
Mar 1, 2008·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yung-Wei Chi, Michael R Jaff
Mar 6, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Yuko Tsurumi-IkeyaSatoshi Umemura
Aug 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Pedro MataJuan Badimón
Jun 17, 2009·Expert Opinion on Pharmacotherapy·Andrew B McCann, Michael R Jaff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
C StefanuttiS Abbolito
© 2021 Meta ULC. All rights reserved